Actively Recruiting
A Study of Sacituzumab Govitecan in People With Mesothelioma
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-05-05
33
Participants Needed
7
Research Sites
260 weeks
Total Duration
On this page
Sponsors
M
Memorial Sloan Kettering Cancer Center
Lead Sponsor
G
Gilead Sciences
Collaborating Sponsor
AI-Summary
What this Trial Is About
Participants will receive sacituzumab govitecan until their disease gets worse (progresses), they have severe side effects and cannot continue study treatment, or the participants or the study doctor thinks it's in your best interest to stop treatment.
CONDITIONS
Official Title
A Study of Sacituzumab Govitecan in People With Mesothelioma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient or legally authorized representative must provide written informed consent
- Patient must be 18 years or older at consent
- Pathologically confirmed diffuse pleural mesothelioma
- Must have received at least one prior systemic therapy (platinum/pemetrexed, immunotherapy, or combination)
- Measurable disease per modified RECIST criteria (or RECIST v1.1 at investigator discretion)
- Consent to biopsy before Cycle 1 Day 1 and Cycle 3 Day 1 if medically safe
- ECOG performance score of 0 or Karnofsky Performance Status of 70% or higher
- Adequate organ function including neutrophil count ≥1.5K/mcL, platelet count ≥100K/mcL, creatinine clearance ≥30 ml/min, hemoglobin >9 g/dL (with exceptions), bilirubin and liver enzymes within specified limits
- Willingness to use highly effective contraception if of childbearing potential starting 1 month before until 2 months after active therapy
You will not qualify if you...
- Participation in another study with investigational therapy within 3 weeks before study start
- Prior hypersensitivity to irinotecan or sacituzumab govitecan-hziy components
- Recent cytotoxic or immunologic systemic therapy within 3 weeks before study Day 1 or unresolved adverse events (except Grade 2 neuropathy)
- Psychiatric or substance abuse disorders interfering with study requirements
- Active additional malignancy requiring treatment (exceptions apply)
- Positive hepatitis B surface antigen (HBsAg) without controlled viral load or ongoing prophylaxis
- Positive hepatitis C antibody without completed treatment and documented viral control
- HIV infection with uncontrolled disease or interfering antiretroviral therapy
- Recent serious cardiac events within 6 months
- Congestive heart failure NYHA Class III-IV or recent hospitalization for heart failure
- Pregnant, breastfeeding, or of childbearing potential not using highly effective contraception as defined
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, United States, 07920
Actively Recruiting
2
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, United States, 07748
Actively Recruiting
3
Memorial Sloan Kettering Bergen
Montvale, New Jersey, United States, 07645
Actively Recruiting
4
Memorial Sloan Kettering Cancer Center @ Commack
Commack, New York, United States, 11725
Actively Recruiting
5
Memorial Sloan Kettering Westchester
Harrison, New York, United States, 10604
Actively Recruiting
6
Memorial Sloan - Kettering Cancer Center
New York, New York, United States, 10021
Actively Recruiting
7
Memorial Sloan Kettering Nassau
Uniondale, New York, United States, 11553
Actively Recruiting
Research Team
M
Michael Offin, MD
CONTACT
R
Robert Daly, MD, MBA
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here